Neuroscience

Hemp plants being used in scientific research
#Cannabinoid #Medicinal cannabis #Neuroscience #Phase I trial #Sapient Therapeutics

Positive Phase I results for solid dose prescription CBD medicine

Positive Phase I results for a new solid dose prescription cannabidiol (CBD) demonstrate the tolerability and bioavailability of the drug. Neuroscience drug discovery company Sapient Therapeutics successfully completed Part B of the Phase I trial comparing its CBD therapy SAP021 with Epidiolex. The trial… Read More

#News

Neuroscience innovation
#AI #Alzheimer's #Artificial intelligence (AI) #Biomarkers #Brain disease #Drug discovery #Inherited tauopathies #Mental health #Nervous system disorders #Neurodegenerative disorders #Neurology #Neuroscience #Neurotechnology #Psychiatry #Tau protein

New podcast on innovation in neuroscience

This is the latest episode of the free DDW narrated podcast, titled “Where is the latest innovation in neuroscience?” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Taking a new approach to tackle neurodegenerative diseases,… Read More

#News

#Cancer research #Dementia #Motor neurone disease #Neuroscience #Osteoarthritis #Schizophrenia

New DDW Highlights episode out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news highlights this week are mostly focused around neuroscience, with new guiding principles… Read More

#News

#Cancer research #Dementia #Motor neurone disease #Neuroscience #Osteoarthritis #Schizophrenia

This week in drug discovery (4-8 December) 

News round-up for 4-8 December by DDW Digital Content Editor Diana Spencer. The news highlights this week are mostly focused around neuroscience, with new guiding principles and a drug repurposing fund launched for motor neuron disease research, a new drug target found for early-onset dementia, and a… Read More

#News

Jigsaw puzzle of the brain
#Cryo-EM #Dementia #Medical Research Council #Motor neurone disease #Neurodegenerative disorders #Neuroscience

Researchers identify potential drug target for early-onset dementia

Scientists have identified abnormal aggregates of a protein called TAF15 in the brains of individuals with early-onset dementia, known as frontotemporal dementia, where the cause was not previously known. The research led by scientists from the Medical Research Council (MRC) Laboratory of Molecular Biology, in Cambridge,… Read More

#Editor's Choice #News

Demyelination of neuron
#ALS #Drug repurposing #LifeArc #Medicines Discovery Catapult #MND Association #Motor neurone disease #Neuroscience

New guiding principles to overcome barriers to MND drug discovery

New guidance for the motor neuron disease (MND) drug discovery community has been published to ensure that future drug discovery and development efforts have the best chance of successfully translating from the lab to the clinic. The whitepaper ‘Guiding principles for drug discovery and development in… Read More

#News #Trending News

#Neumora Therapeutics #Neuropsychiatric disorders #Neuroscience #Phase I trial #Schizophrenia #Vanderbilt University

Potentially game-changing schizophrenia drug enters trials

A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials. NMRA-266, an allosteric modulator that works through a mechanism that has been clinically validated in the treatment of disorders like… Read More

#Editor's Choice #News #Regulatory

#Alzheimer's #Computer modelling #Neurodegenerative disorders #Neuroscience #Penn State University #Predictive diagnostics

Mathematical model can speed up Alzheimer’s drug development

Researchers have created a mathematical model that can accurately predict Alzheimer’s disease progression in individual patients, paving the way for personalised treatment and faster development of therapies. According to the model, the disease onset and rate of progression varies on a case by case basis, meaning… Read More

#Editor's Choice #News

Neurons
#Harvard Medical School #Mission Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #University of Cambridge

Potential disease-modifying therapy for Parkinson’s disease

An experimental drug has shown potential as a disease-modifying therapy for Parkinson’s disease, according to a new study published in Nature Communications. The peer-reviewed article titled ‘Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease (PD) mouse model’ was the result of collaborative… Read More

#Editor's Choice #News

Neurons in Parkinson's disease
#Cerevance #Neurodegenerative disorders #Neuroscience #Parkinson's #Phase II trial

First-in-class non-dopamine Parkinson’s therapy enters Phase II

Cerevance has dosed the first patient in its ASCEND Phase II study to assess the efficacy and safety of CVN424 as a monotherapy in early-stage Parkinson’s disease. In February 2023 the company expanded its Series B funding round, raising a total of $116 million. … Read More

#News

Neuron
#Antidepressants #Biomarkers #Depression #Gate Neurosciences #Neuroscience #Phase I trial

Phase I clinical trial validates qEEG biomarker in CNS disorders

Gate Neurosciences has announced positive topline quantitative EEG (qEEG) biomarker and safety results from its Phase I multiple ascending dose study of apimostinel in healthy volunteers. The results demonstrated a dose-dependent increase in qEEG pharmacodynamic biomarkers of NMDA receptor target activation from baseline, compared with subjects… Read More

#News

Alcohol use disorder
#Alcohol Use Disorder #Kinnov Therapeutics #Neuroscience #Phase II trial

Drug halves alcohol consumption to aid alcohol dependence

Kinnov Therapeutics’ Phase II study for its lead compound KT-110 has shown that the treatment can halve alcohol consumption amongst heavy drinkers in three months. The trial showed that KT-110 has superior efficacy in significantly reducing alcohol consumption in heavy drinkers by 26 to 30 grams… Read More

#News

#Biotechnology #Concussion #Neurology #Neuroscience #Oxeia Biopharmaceuticals #University of Kansas Medical Center (KUMC)

“Game changing” concussion drug study shows positive early results  

Oxeia Biopharmaceuticals, a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, has announced “game-changing” results of a Phase IIa pilot study of OXE103 at the University of Kansas Medical Center (KUMC).   The study results suggest a potentially… Read More

#News

Active nerve cells
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

Innovative advances in neuroscience: Secure your place

It’s less than one week now till our exclusive online event ‘Innovative advances in neuroscience’, hosted by DDW and sponsored by ACRO Biosystems. Register now to secure your place on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. You… Read More

Webinar date:
#News

#Biomarkers #Drug discovery #Neurodegenerative disorders #Neuroscience

Could NfL accelerate drug development for neurodegenerative diseases?

Listen to this article on the DDW Podcast: Professor Andy Whiting and Dr Tony Lockett discuss how specific levels of a protein could be used to advance drug development in neurodegenerative diseases. Neurofilament light (NfL) analysis is a potential biomarker for damage to both the central and peripheral nervous system. It… Read More

#Exclusive Content

Neurons
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

Innovation in neuroscience: Hear from the experts

Register now to hear from neuroscience industry experts at ‘Innovative advances in neuroscience’, hosted by DDW and sponsored by ACRO Biosystems. The online event will be free to attend on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. You… Read More

Webinar date:
#News